VRTX
Vertex Pharmaceuticals Inc
NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY
$444.93
-0.03% today
Updated 2026-06-12
Market cap
$107.89B
P/E ratio
25.26
P/S ratio
8.83x
EPS (TTM)
$16.83
Dividend yield
—
52W range
$363 – $508
Volume
1.2M
Vertex Pharmaceuticals Inc (VRTX) Insider transactions
Net insider activity
Net selling (109,075 shares)
Buy transactions
27
Sell transactions
73
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-01 | LIU, JOY | EVP and Chief Legal Officer | Sale | 828 | $439.91 | $364245.48 |
| 2026-05-29 | BOZIC, CARMEN | EVP and CMO | Sale | 1,974 | $450.00 | $888300.00 |
| 2026-05-15 | BUNNAGE, MARK E. | EVP, Chief Scientific Officer | Sale | 33 | $453.45 | $14963.85 |
| 2026-05-15 | BOZIC, CARMEN | EVP and CMO | Sale | 1,354 | $453.45 | $613971.30 |
| 2026-05-12 | BOZIC, CARMEN | EVP and CMO | Sale | 6,988 | $450.00 | $3.14M |
| 2026-05-04 | BHATIA, SANGEETA N. | Director | Sale | 318 | $423.73 | $134746.14 |
| 2026-05-01 | UPADHYAY, SUKETU | Director | Buy | 2,866 | — | — |
| 2026-05-01 | UPADHYAY, SUKETU | Director | Buy | 796 | — | — |
| 2026-05-01 | UPADHYAY, SUKETU | Director | Sale | 796 | — | — |
| 2026-05-01 | THORNBERRY, NANCY | Director | Buy | 1,433 | — | — |
| 2026-05-01 | THORNBERRY, NANCY | Director | Buy | 398 | — | — |
| 2026-05-01 | THORNBERRY, NANCY | Director | Buy | 472 | — | — |
| 2026-05-01 | THORNBERRY, NANCY | Director | Sale | 398 | — | — |
| 2026-05-01 | SCHNEIDER, JENNIFER | Director | Buy | 1,433 | — | — |
| 2026-05-01 | SCHNEIDER, JENNIFER | Director | Buy | 796 | — | — |
| 2026-05-01 | SCHNEIDER, JENNIFER | Director | Sale | 796 | — | — |
| 2026-05-01 | SCHNEIDER, JENNIFER | Director | Buy | 472 | — | — |
| 2026-05-01 | SACHS, BRUCE I | Director | Buy | 2,866 | — | — |
| 2026-05-01 | MCKENZIE, DIANA | Director | Buy | 796 | — | — |
| 2026-05-01 | MCKENZIE, DIANA | Director | Buy | 943 | — | — |
| 2026-05-01 | MCKENZIE, DIANA | Director | Sale | 796 | — | — |
| 2026-05-01 | LIU, JOY | EVP and Chief Legal Officer | Sale | 1,104 | $425.02 | $469222.08 |
| 2026-05-01 | LAGARDE, MICHEL | Director | Buy | 2,866 | — | — |
| 2026-05-01 | GARBER, ALAN M | Director | Buy | 1,433 | — | — |
| 2026-05-01 | GARBER, ALAN M | Director | Buy | 472 | — | — |
| 2026-05-01 | CARNEY, LLOYD | Director | Buy | 2,866 | — | — |
| 2026-05-01 | BHATIA, SANGEETA N. | Director | Buy | 943 | — | — |
| 2026-04-15 | UPADHYAY, SUKETU | Director | Buy | 81 | $442.50 | $35842.50 |
| 2026-04-15 | SACHS, BRUCE I | Director | Buy | 107 | $442.50 | $47347.50 |
| 2026-04-15 | GARBER, ALAN M | Director | Buy | 34 | $442.50 | $15045.00 |
| 2026-04-01 | LIU, JOY | EVP and Chief Legal Officer | Sale | 978 | $449.17 | $439288.26 |
| 2026-03-27 | BOZIC, CARMEN | EVP and CMO | Sale | 2,329 | $450.95 | $1.05M |
| 2026-03-13 | BOZIC, CARMEN | EVP and CMO | Sale | 2,329 | $481.79 | $1.12M |
| 2026-03-11 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 2,633 | $498.42 | $1.31M |
| 2026-03-04 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 2,437 | $475.30 | $1.16M |
| 2026-03-02 | LIU, JOY | EVP and Chief Legal Officer | Sale | 892 | $495.96 | $442396.32 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 15,580 | $495.38 | $7.72M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 5,995 | $496.16 | $2.97M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 3,498 | $494.33 | $1.73M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 3,278 | $488.27 | $1.60M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 2,725 | $490.54 | $1.34M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 2,520 | $493.29 | $1.24M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 2,510 | $487.13 | $1.22M |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 1,725 | $496.95 | $857238.75 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 949 | $491.30 | $466243.70 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 460 | $489.32 | $225087.20 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 400 | $479.75 | $191900.00 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 240 | $482.84 | $115881.60 |
| 2026-02-27 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 120 | $481.50 | $57780.00 |
| 2026-02-27 | BOZIC, CARMEN | EVP and CMO | Sale | 2,329 | $480.31 | $1.12M |
| 2026-02-26 | AMBROSE, KRISTEN | SVP & Chief Accounting Officer | Sale | 357 | $483.36 | $172559.52 |
| 2026-02-25 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Sale | 260 | $486.35 | $126451.00 |
| 2026-02-25 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 1,846 | $486.35 | $897802.10 |
| 2026-02-25 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 2,500 | $486.35 | $1.22M |
| 2026-02-25 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 2,410 | $489.00 | $1.18M |
| 2026-02-25 | BUNNAGE, MARK E. | EVP, Chief Scientific Officer | Sale | 620 | $486.35 | $301537.00 |
| 2026-02-25 | BILLER, JONATHAN | EVP and Chief Legal Officer | Sale | 945 | $486.35 | $459600.75 |
| 2026-02-25 | ATKINSON, EDWARD MORROW III | EVP, Chief Technical Ops. Off. | Sale | 668 | $486.35 | $324881.80 |
| 2026-02-25 | AMBROSE, KRISTEN | SVP & Chief Accounting Officer | Sale | 223 | $486.35 | $108456.05 |
| 2026-02-24 | WAGNER, CHARLES F JR | EVP, CO & FO | Sale | 1,744 | $485.11 | $846031.84 |
| 2026-02-24 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Sale | 1,627 | $485.11 | $789273.97 |
| 2026-02-24 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 1,518 | $485.11 | $736396.98 |
| 2026-02-24 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 873 | $485.11 | $423501.03 |
| 2026-02-24 | LEIDEN, JEFFREY M | Director, Executive Chairman | Sale | 3,547 | $485.11 | $1.72M |
| 2026-02-24 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 4,981 | $485.11 | $2.42M |
| 2026-02-24 | BUNNAGE, MARK E. | EVP, Chief Scientific Officer | Sale | 582 | $485.11 | $282334.02 |
| 2026-02-24 | BOZIC, CARMEN | EVP and CMO | Sale | 1,453 | $485.11 | $704864.83 |
| 2026-02-24 | BILLER, JONATHAN | EVP and Chief Legal Officer | Sale | 1,144 | $485.11 | $554965.84 |
| 2026-02-24 | ATKINSON, EDWARD MORROW III | EVP, Chief Technical Ops. Off. | Sale | 1,627 | $485.11 | $789273.97 |
| 2026-02-24 | AMBROSE, KRISTEN | SVP & Chief Accounting Officer | Sale | 546 | $485.11 | $264870.06 |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 25,026 | — | — |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 23,479 | — | — |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Buy | 25,026 | $187.53 | $4.69M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Buy | 23,479 | $155.57 | $3.65M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 19,662 | $468.57 | $9.21M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 11,712 | $470.54 | $5.51M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 10,263 | $467.75 | $4.80M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 7,241 | $469.61 | $3.40M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 4,237 | $471.43 | $2.00M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 2,730 | $465.05 | $1.27M |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 1,848 | $465.80 | $860798.40 |
| 2026-02-19 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 920 | $463.91 | $426797.20 |
| 2026-02-18 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Sale | 368 | $473.68 | $174314.24 |
| 2026-02-18 | LEIDEN, JEFFREY M | Director, Executive Chairman | Sale | 2,964 | $483.75 | $1.43M |
| 2026-02-18 | BUNNAGE, MARK E. | EVP, Chief Scientific Officer | Sale | 1,182 | $473.68 | $559889.76 |
| 2026-02-18 | BILLER, JONATHAN | EVP and Chief Legal Officer | Sale | 1,244 | $473.68 | $589257.92 |
| 2026-02-18 | ATKINSON, EDWARD MORROW III | EVP, Chief Technical Ops. Off. | Sale | 817 | $473.68 | $386996.56 |
| 2026-02-18 | AMBROSE, KRISTEN | SVP & Chief Accounting Officer | Sale | 638 | $473.68 | $302207.84 |
| 2026-02-17 | WAGNER, CHARLES F JR | EVP, CO & FO | Buy | 7,365 | — | — |
| 2026-02-17 | WAGNER, CHARLES F JR | EVP, CO & FO | Sale | 2,294 | $483.75 | $1.11M |
| 2026-02-17 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Buy | 5,789 | — | — |
| 2026-02-17 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Sale | 2,294 | $483.75 | $1.11M |
| 2026-02-17 | TATSIS, OURANIA | EVP, Chief Reg. & Quality Off. | Sale | 609 | $489.46 | $298081.14 |
| 2026-02-17 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Buy | 5,789 | — | — |
| 2026-02-17 | SACHDEV, AMIT | EVP Chief Patient & Ext Af Off | Sale | 2,140 | $483.75 | $1.04M |
| 2026-02-17 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Buy | 4,962 | — | — |
| 2026-02-17 | MCKECHNIE, DUNCAN | EVP, Chief Commercial Officer | Sale | 1,148 | $483.75 | $555345.00 |
| 2026-02-17 | LEIDEN, JEFFREY M | Director, Executive Chairman | Buy | 8,269 | — | — |
| 2026-02-17 | KEWALRAMANI, RESHMA | Director, CEO & President | Buy | 16,326 | — | — |
| 2026-02-17 | KEWALRAMANI, RESHMA | Director, CEO & President | Sale | 6,554 | $483.75 | $3.17M |
Frequently asked questions
Are VRTX insiders buying or selling?
Over the transactions on record, VRTX insiders have been net sellers, with about $84.53M in stock sold across 73 sales, against 5 open-market purchases.
Does insider selling at VRTX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which VRTX insiders are selling the most?
Recent selling is concentrated in a few names. SACHDEV, AMIT accounts for the largest share on record, with about $30.15M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.